Skip to main content

Zentalis Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

ZNTL$1.74+1.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

ExhibitNumber · Description · Incorporated by Reference
Form · File No. · Exhibit · FilingDate · Filed/Furnished Herewith
2.1Plan of Conversion Converting Zentalis Pharmaceuticals, LLC (a Delaware limited liability company) into Zentalis Pharmaceuticals, Inc. (a Delaware corporation)10-Q001-392632.105/15/2020
2.2Certificate of Conversion Converting Zentalis Pharmaceuticals, LLC (a Delaware limited liability company) into Zentalis Pharmaceuticals, Inc. (a Delaware corporation)10-Q001-392632.205/15/2020
3.1Certificate of Incorporation of Zentalis Pharmaceuticals, Inc.S-8333-2375934.104/07/2020
3.2Certificate of Amendment to Certificate of Incorporation of Zentalis Pharmaceuticals, Inc., dated June 16, 20238-K001-392633.106/16/2023
3.3Amended and Restated Bylaws of Zentalis Pharmaceuticals, Inc.8-K001-392633.102/15/2024
ExhibitNumberDescriptionIncorporated by Reference
FormFile No.ExhibitFilingDateFiled/Furnished Herewith
10.1†Release Agreement, dated August 19, 2024, among Zentalis Pharmaceuticals, Inc., Zeno Management, Inc., and Diana Hausman, M.D.*
31.1Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a).*
31.2Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).*
32.1Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.**
32.2Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.**
101.INSInline XBRL Instance Document*
101.SCHInline XBRL Taxonomy Extension Schema Document*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
104Cover Page Interactive Data file (formatted as inline XBRL and contained in Exhibit 101)*
  • Filed herewith.

** Furnished herewith.

† Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.